OncoCyte Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- AppLovin gains market share among e-commerce advertisers
- Wall Street ends higher as investors turn to earnings season
OncoCyte (OCX) Prices 9.33M Common Stock Offering at $3.75/Share
February 8, 2019 9:01 AM ESTOncoCyte Corporation (NYSE American: OCX) (OncoCyte), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the pricing of an underwritten public offering of 9,333,334 shares of its common stock at a public offering price of $3.75 per share, for aggregate gross... More
